Colleen Kusy
Stock Analyst at Baird
(0.84)
# 3,784
Out of 4,876 analysts
47
Total ratings
26.83%
Success rate
-17.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $80.97 | +38.32% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $20.97 | +147.97% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $4.99 | +20.24% | 4 | Jun 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $55 → $47 | $17.60 | +167.05% | 11 | May 8, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $19.35 | +111.94% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $0.75 | +703.11% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $15.63 | +315.87% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.32 | +834.58% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $9.14 | +86.00% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $10.37 | +141.08% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.39 | +4,683.60% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.68 | +1,923.81% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.78 | +12,851.07% | 1 | Nov 2, 2021 |
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $80.97
Upside: +38.32%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $20.97
Upside: +147.97%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $4.99
Upside: +20.24%
Apellis Pharmaceuticals
May 8, 2025
Maintains: Outperform
Price Target: $55 → $47
Current: $17.60
Upside: +167.05%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $19.35
Upside: +111.94%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.75
Upside: +703.11%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $15.63
Upside: +315.87%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.32
Upside: +834.58%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $9.14
Upside: +86.00%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $10.37
Upside: +141.08%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.39
Upside: +4,683.60%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.68
Upside: +1,923.81%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.78
Upside: +12,851.07%